Background {#Sec1}
==========

Antimicrobial resistance (AMR) is a growing global threat because in addition to its appreciable clinical impact, it also has a considerable economic impact \[[@CR1], [@CR2]\]. Therefore, it is necessary to reduce the prescription of inappropriate antibiotics and to control the spread of resistant bacteria not only in developing countries, but also in developed countries \[[@CR2], [@CR3]\]. Accordingly, the Japanese government developed the National Action Plan on Antimicrobial Resistance 2016--2020 in 2016 \[[@CR4]\]. A prominent feature of the national action plan was the specification of outcome measures, including a reduction of antibiotic consumption and a reduction of the resistance rate. To achieve these outcomes, each health facility in Japan has implemented an antimicrobial stewardship (AS) program which aimed to stop the use of unnecessary antibiotics.

A common setting for antibiotic overuse is in the treatment of upper respiratory tract infections (URIs). The majority of URIs are viral \[[@CR5]\], and the administration of antibiotics in the treatment of these conditions, or in preventing complications, has limited effectiveness \[[@CR6]\]. In Japan, antibiotics were prescribed in 60% of clinical visits due to URIs, with third-generation cephalosporins, macrolides, and fluoroquinolones being among the most commonly prescribed antibiotics \[[@CR7]\].

A high percentage (\> 94%) of antimicrobials prescribed are oral antibiotics in Japan \[[@CR8]\]. The use of oral antibiotics is reportedly higher in children (\< 15 years) and the elderly (≥65 years) than in individuals aged 15--64 years \[[@CR9]\]. Additionally, the highest prescription rates of all antimicrobials is among children aged 1--5 years, peaking at age 1 year \[[@CR10]\]. Efforts to improve antibiotic prescribing practices need to incorporate some complementary strategies: changing physicians' behavior \[[@CR11]\], patient education, and modifying the healthcare system \[[@CR12], [@CR13]\].

In response to the current situation in Japan, the Japanese government developed the Manual of Antimicrobial Stewardship based on the national action plan on AMR in 2017 \[[@CR14]\], and as a completely new and unique approach revised the Japanese medical reimbursement system in 2018, introducing a fee for the implementation of AS for pediatric patients with URIs of 800 Yen (approximately \$7.5 US) for the first visit \[[@CR15]\]. Pediatricians can claim the AS fee provided that they (1) have examined the patient for acute URI or acute diarrhea, with no other underlying condition, and (2) provide proof that they have provided education to the responsible adult on the condition for which they were consulted, including the lack of necessity for antibiotics.

In Japan, citizens have unrestricted access to medical care due to the public insurance system. A recent survey reported that 30.1% of patients want to be prescribed antibiotics for a common cold \[[@CR16]\]. The implementation of the AS fee raised concerns that patients may seek care elsewhere if they were not prescribed antibiotics. Therefore, the purpose of this study was to evaluate the physician's prescription and the patient's behavior with respect to the management of pediatric patients with URIs following the implementation of the AS fee using claims data.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

We conducted a retrospective observational study from January 1, 2017 to September 30, 2018. Data were obtained from the claims database, IQVIA Claims, which collects data of corporate employees and their family members. This database consists of anonymized inpatient, outpatient and pharmacy claims data on \> 2.3 million individuals aged \< 75 years from 32 Society-Managed Health Insurance institutions. The data accounts for approximately 5% of the total number of claims. In addition, the database includes patient characteristics (sex, and 5-year age group), prescription drug information (brand name, generic name, prescription date, duration), diagnostic information (date of the initial diagnosis and treatment days), treatment procedure (operation, radiation, examination, etc.), and hospital characteristics (classified according to the number of beds and specialty).

The study was performed in accordance with the Declaration of Helsinki and the study protocol was approved by the Ethics Committee of Kyoto Pharmaceutical University (No. 19--13). As this study used only anonymized claims data, the requirement for the consent was waived according to the requirements of the Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects \[[@CR17]\].

Patients {#Sec4}
--------

We evaluated pediatric patients aged \< 15 years who visited outpatient clinics for treatment of an acute URI or acute tonsillitis, as identified by their respective Japanese disease codes (4,659,007 and 8,832,289). To assess the antibiotic prescription pattern for the treatment of URIs before and after the AS fee was implemented, we extracted data for pediatric URIs diagnosed during the study period, and divided them according to whether the medical facility had claimed the AS fee (Fig. [1](#Fig1){ref-type="fig"}). Children who met all the following conditions were included in the study: (1) diagnosed with URIs in the survey period; (2) aged \< 15 years in the month of diagnosis; (3) pediatrician claimed an initial visit fee in the month of diagnosis; (4) had been diagnosed with another condition within the 3 months prior to the URI diagnosis and had not been hospitalized. Additionally, we evaluated the impact of the AS fee on antibiotic prescription according to age group. Fig. 1Timeframe for data extraction. Patients who met all the following conditions were enrolled in this study: (1) diagnosed with an upper respiratory tract infection (URI) during the survey period; (2) aged \< 15 years in the month of diagnosis; (3) pediatrician claimed an initial visit fee in the month of diagnosis; (4) diagnosed with a different condition within 3 months prior to the diagnosis of the URI and not hospitalized (Lookback\*).URI: upper respiratory tract infection

Data collection {#Sec5}
---------------

Antibiotics were classified according to Level 4 of the Anatomical Therapeutic Chemical Classification System. We classified antibiotic use according to the number of antibiotics prescribed and evaluated the proportion of each class in relation to the total number of antibiotics prescribed. We also determined whether the same patient visited multiple facilities during the study period.

Statistical analysis {#Sec6}
--------------------

Data analysis was performed using JMP Pro 14 (SAS Institute Inc., Cary, NC, USA) and IBM SPSS Statistics 23 (IBM, Armonk, NY, USA). Most of the results were reported as frequencies and proportions. Pearson's chi-square test was used to test for statistical significance of the differences in the proportion of children prescribed an antibiotic before and after the introduction of the AS fee. Statistical significance was defined as a *p*-value \< 0.05.

Results {#Sec7}
=======

Figure [2](#Fig2){ref-type="fig"} shows the process for selecting children for inclusion in the analysis, and the number of children who were excluded because they did not meet the inclusion criteria. There were 31,137 children who met the criteria for inclusion in the "Before" group, and 30,502 children who met the criteria for inclusion in the "After" group. Fig. 2Flowchart showing patient selection and the number of exclusions due to ineligibility. \* We excluded multiple visits during the analysis period. AS: antimicrobial stewardship

The frequency of antibiotic prescription for URIs decreased significantly after the AS fee implementation, regardless of whether the facility claimed the fee (Fig. [3](#Fig3){ref-type="fig"}). Fig. 3Impact of the antimicrobial stewardship fee on the rate of antibiotic prescription. We divided the number of patients visiting a hospital by the rate of antibiotic prescription to calculate the percentages in the graph. \*Pearson's chi-square test, AS: antimicrobial stewardship

The frequency of antibiotic prescription was lower in facilities that claimed the AS fee than in facilities that did not both before and after AS fee implementation. Additionally, the magnitude of the decrease was similar in facilities that claimed the AS fee (6.03, 95% confidence interval \[CI\]: 4.74--7.32%) and those that did not claim the AS fee (4.84, 95% CI: 3.95%--5.73), but there was no marked change in the overall antibiotic prescribing pattern (Table [1](#Tab1){ref-type="table"}). Table 1Antibiotic prescription frequency before and after the implementation of the antimicrobial stewardship fee^a^Medical facilities that claimed the AS fee^b^Medical facilities that did not claim the AS fee^b^All medical facilities^b^BeforeAfterBeforeAfterBeforeAfterTetracyclines (J01AA)15 (0.5)6 (0.3)40 (0.4)26 (0.3)55 (0.4)32 (0.3)Penicillins (J01CA, CE)551 (19.3)540 (23.7)1559 (16.0)1572 (19.0)2110 (16.8)2112 (20.0)Combinations of penicillins, including beta-lactamase inhibitors (J01CR)37 (1.3)35 (1.5)269 (2.8)246 (3.0)306 (2.4)281 (2.7)First-generation cephalosporins (J01DB)27 (0.9)13 (0.6)44 (0.5)46 (0.6)71 (0.6)59 (0.6)Second-generation cephalosporins (J01DC)29 (1.0)27 (1.2)82 (0.8)82 (1.0)111 (0.9)109 (1.0)Third-generation cephalosporins (J01DD)1426 (50.1)1032 (45.2)4714 (48.4)3776 (45.7)6140 (48.8)4808 (45.6)Other beta-lactams (J01DE, DF, DH)39 (1.4)26 (1.1)180 (1.1)147 (1.8)219 (1.7)173 (1.6)Combinations of sulfonamides and trimethoprim, incl. Derivatives (J01EE)0 (0.0)0 (0.0)2 (0.0)1 (0.0)2 (0.0)1 (0.0)Macrolides (J01FA10)567 (19.9)472 (20.7)2272 (23.4)1880 (22.7)2839 (22.6)2352 (22.3)Fluoroquinolones (J01MA)117 (4.1)100 (4.4)457 (4.7)385 (4.7)574 (4.6)485 (4.6)Aminoglycosides (J01GA, GB)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Glycopeptide antibacterials (J01XA)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)0 (0.0)Other antibacterials (J01XB-XX)41 (1.4)32 (1.4)111 (1.1)106 (1.3)152 (1.2)138 (1.3)Total284922839730826712,57910,550^a^The values are based on the information from the participating facilities claiming the antimicrobial stewardship fee or not^b^The values show the total frequency of prescription (proportion)Abbreviations: *AS* antimicrobial stewardship

The frequency of antibiotic prescription for URIs decreased significantly in all age groups after AS fee implementation (*p* \< 0.001, Fig. [4](#Fig4){ref-type="fig"}). Despite the reduced frequency of antibiotic prescription, consultation behavior did not change, and the majority of children had only one medical facility visit before (97.3%) and after (97.4%) implementation of the AS fee (*p* = 0.06). Fig. 4Antibiotic prescription frequency before and after antimicrobial stewardship fee implementation, according to age. The number of patients visiting a hospital was divided by the rate of antibiotic prescription to calculate the percentages in the graph. \* Pearson's chi-square test

Discussion {#Sec8}
==========

After the implementation of the AS fee, the frequency of prescriptions for children with URIs decreased at both facilities that did, and did not claim the AS fee, and the frequency of antibiotics decreased in all age groups. However, there was no marked change in either the frequency of consultations, or in the overall prescribing pattern.

In this study, the frequency of prescriptions for children with URIs decreased regardless of the type of facility. It has been reported that educational interventions, awareness-raising activities, feedback on social norms, and restrictions have reduced the frequency of prescriptions \[[@CR11], [@CR13], [@CR18]\]. In Japan, the AMR Clinical Reference Center (AMRCRC) was established in 2017 as a commissioned project by the Ministry of Health, Labor and Welfare. The AMRCRC is mainly overseeing the awareness activities for AMR toward public and medical professionals, the construction of surveillance systems, and the release of epidemiological data \[[@CR19], [@CR20]\]. Therefore, it has been suggested that these activities may influence prescription frequency regardless of whether there is an AS fee claim. On the other hand, the finding that the frequency of prescriptions tends to be less in medical facilities that claimed the AS fee, suggests that having a system that rewards medical facilities that take appropriate action is an important measure.

The use of antibiotics in children peaks at the age of one year in Japan \[[@CR10]\]. In other countries antibiotics also tend to be prescribed more frequently in younger children \[[@CR21]\]. Notably, this intervention reduced prescriptions among patients of all ages. This suggests that the AS program may change physicians' overall prescribing behavior.

In October 2017, the estimated number of patients with acute URIs aged \< 15 years was 113,500 per day, and the number of pediatric clinics was 19,647 \[[@CR22]\]. One clinic reported that the AS fee increased the average amount spent per patient from 5490 Yen in FY 2017, to 6300 Yen in FY 2018 (unpublished data), so the cost related to the AS fee might be low as a proportion of the total medical fee. There have been reports on the giving of incentives to hospitals, general practitioners, and county units for the reduction of antibiotic prescriptions in England \[[@CR23], [@CR24]\] and Sweden \[[@CR25]\]. However, our approach to providing incentives for physicians' behavior, to not only reduce antibiotic prescribing but also to provide education to patients is, to our knowledge, unique to Japan. Although mid- to long-term evaluation is necessary, the approach used in our study might also be effective in reducing inappropriate antibiotic use in other countries.

Our study did not show an increase in multiple consultations after the implementation of the AS fee. The AS fee provides doctors with an incentive not to prescribe antibiotics at the first visit and rewards them when they manage and educate patients without prescribing antibiotics \[[@CR15]\]. It is assumed that children's parents will be satisfied with the explanations that the doctor has provided.

This study has some limitations. Firstly, it is not an evaluation of the entire population because it only targeted children and used the claims data from 32 Society-Managed Health Insurance institutions responsible for about 5% of claims; thus, the generalizability of the findings might be limited. However, it provides valuable information for evaluating the effectiveness of the AS fee using claims data. A national database could be used in future studies to broaden the generalizability of the findings. Another limitation is that individual patient outcomes could not be evaluated. The results might have also been influenced by the physician not prescribing antibiotics on the first visit. Additionally, the analysis period was less than a year because the claims database could not yet be obtained when we conducted this study. Our research provides vital information that can be a basis for implementing AS fees in other countries. This methodology that evaluated using claims data might also be valuable in other medical reimbursement systems.

Conclusion {#Sec9}
==========

In conclusion, although the frequency of antibiotic prescriptions decreased regardless of whether the facility claimed the AS fee, the AS fee helps to limit unnecessary antibiotic prescription without affecting patient behavior. Thus, the AS fee system can be considered an effective strategy against AMR.
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